Ge Long Hui·2026-02-26 09:06Core Insights - The company reported a total revenue of approximately RMB 1,067.91 million for the fiscal year 2025, representing a year-on-year growth of 26.18% [1] - The net profit attributable to the parent company was approximately RMB 27.87 million, marking a turnaround from a loss in the previous year [1] - The net loss attributable to the parent company, excluding non-recurring gains and losses, was approximately RMB 92.50 million [1] Financial Performance - The operating profit, total profit, and net profit attributable to the parent company all achieved a turnaround from losses to profits year-on-year [2] - Basic earnings per share and the weighted average return on equity turned positive [2] - The net loss attributable to the parent company, excluding non-recurring gains and losses, narrowed year-on-year, primarily due to the revenue growth and cost-saving measures implemented by the company [2] Strategic Developments - The company continues to focus on innovation and commercialization, with the first quadrivalent meningococcal vaccine, Manhaixin, maintaining steady growth [1] - The company has effectively controlled various expenses and optimized production and sales coordination, leading to an improvement in gross margin [1] - The company received government special subsidies and international research funding, contributing to non-recurring income during the reporting period [1]